Albert Fleury Email & Phone Number

Rockville, Md

Lead Cryopreserved Platelet Business Unit including: management of ongoing multi-year US Army Medical Research Acquisition Activity(USAMRAA) contract, ongoing Phase 2/3 clinical trial in cardiac surgery patients, and CMC/product development activities. Additional work in support of Cryopreserved Platelet business strategy including product optimization & next generation planning; initial supply/sourcing work for scaleup; and ex-US partnerships & strategyBusiness development & capital support including identifying and pursuing non-dilutive funding for strategic initiatives; supporting equity raise activities to accelerate value creation; and supporting business development & capital markets efforts (e.g. IP, M&A, IPO)

Cordex Systems Inc. is a privately held early-stage US medical device company focused on designing and clinically testeing a new cardiovascular diagnostic device. As President, COO and CFO I managed all operational and financial aspect of this exciting early stage healthcare and medical device company .

Washington Dc

Defining opportunities for novel medical and diagnostic technologies in heathcare and working with venture backed companies to formulate strategies to address those opportunities.

Directed M&A corporate finance activities and North American investor relations activities, reporting to CFO and VP Business Development for multinational company headquartered in Hilden, Germany• Redesigned and implemented financial valuation practices and methodology for M&A activities used to value and complete over 10 transactions totaling more than $500M• Led financial valuation, due diligence, market and strategic analysis of acquisition targets concentrated in healthcare, molecular technologies and diagnostics including Cellestis LTD (acquired for $350M) and Biotage AB (acquired for $53M) • Led road show with CEO for capital market activities including $557M follow-on equity offering• Served on SEC Disclosure Committee, led annual post acquisition valuation analysis, and supported SEC reporting for a Foreign Private Issuer (FPI)• Communicated an in-depth understanding of all facets of the business to investors and analysts, interacting directly with all internal operational areas • Served as lead contact for largest external shareholders owning up to $150M

Set up investor relations department, reporting to CEO/President and CFO, for publicly traded, US based molecular diagnostics company as management grew revenues from $37M to $202M and transitioned P&L to profitability, with market capitalization increasing from $500M to $1.5B• Led and participated in multiple related areas of QIAGEN’s $1.6B acquisition of Digene (Closed - June 2007), including communicating the financial and strategic rationale of the transaction to investors and integrating the company with QIAGEN• Led road shows with CFO for $97M secondary equity offering, requiring 27 meetings in eight cities over 5 days• Effectively communicated key 2nd FDA approval, working in partnership with all functional areas, increasing access expanded market from $50M to more than $500M• Supported due diligence activities and evaluated strategic aspects of potential acquisition targets working with outside investment bankers and legal counsel• Communicated successful navigation through blocked merger effort with Cytyc Corporation (Announced - February 2002; Blocked by US Federal Trade Commission – June 2002)

Mba, Finance

Bs, Dual Major: Economics / Molecular Biology